Education
About Us
Working with TipRanks
Follow Us
Protara Therapeutics (TARA)
NASDAQ:TARA
TARA Stock Chart & Stats
$5.42
-$0.26(-4.26%)
At close: 4:00 PM EST
$5.42
-$0.26(-4.26%)
Day’s Range― - ―
52-Week Range$2.77 - $7.82
Previous CloseN/A
Volume145.20K
Average Volume (3M)1.00M
Market Cap
$279.84M
Enterprise Value$54.87M
Total Cash (Recent Filing)$132.67M
Total Debt (Recent Filing)$3.66M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Mar 11, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding51,630,737
10 Day Avg. Volume1,683,882
30 Day Avg. Volume1,001,262
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio-3.03
Enterprise Value/Market Cap0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-623.52
Enterprise Value/Ebitda-0.97
Forecast
1Y Price Target
$25.00Price Target Upside361.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessProtara announced interim data from the Phase 2 ADVANCED-2 trial of TARA-002 in BCG-naïve NMIBC patients, meeting critical efficacy and durability benchmarks necessary for emerging drugs to compete in the BCG-naïve setting.
Market OpportunityOngoing BCG shortages leave physicians with limited treatment options for HR patients, which presents an opportunity that TARA-002 is well positioned to fill based on its simple administration, safety profile, and promising early efficacy data.
Regulatory ApprovalProtara received FDA alignment on a pivotal trial design for their bladder cancer drug, TARA-002, in BCG-Naive patients.
Bears Say
Benchmarking ConcernsQuestions remain regarding how TARA-002’s performance will be benchmarked against BCG standard of care when it is not directly compared to BCG treatment.
Financial ConstraintsThe company has approximately 1.6 years of cash left, indicating potential financial constraints in the near future.
Investor SkepticismThe company faces a short interest of 8% of its float, which could indicate skepticism among investors.
Protara Therapeutics News
TARA FAQ
What was Protara Therapeutics’s price range in the past 12 months?
Protara Therapeutics lowest stock price was $2.77 and its highest was $7.82 in the past 12 months.
What is Protara Therapeutics’s market cap?
Protara Therapeutics’s market cap is $279.84M.
When is Protara Therapeutics’s upcoming earnings report date?
Protara Therapeutics’s upcoming earnings report date is Mar 11, 2026 which is in 83 days.
How were Protara Therapeutics’s earnings last quarter?
Protara Therapeutics released its earnings results on Nov 10, 2025. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.384 by $0.074.
Is Protara Therapeutics overvalued?
According to Wall Street analysts Protara Therapeutics’s price is currently Undervalued.
Does Protara Therapeutics pay dividends?
Protara Therapeutics does not currently pay dividends.
What is Protara Therapeutics’s EPS estimate?
Protara Therapeutics’s EPS estimate is -0.35.
How many shares outstanding does Protara Therapeutics have?
Protara Therapeutics has 51,630,737 shares outstanding.
What happened to Protara Therapeutics’s price movement after its last earnings report?
Protara Therapeutics reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.384. Following the earnings report the stock price went up 5.594%.
Which hedge fund is a major shareholder of Protara Therapeutics?
Currently, no hedge funds are holding shares in TARA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protara Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.00 (361.25% Upside)
$25.00 (361.25% Upside)
Blogger Sentiment
Bullish
TARA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.98%
12-Months-Change
Fundamentals
Return on Equity
-49.42%
Trailing 12-Months
Asset Growth
53.72%
Trailing 12-Months
Company Description
Protara Therapeutics
Protara Therapeutics (TARA) is a clinical-stage biopharmaceutical company focused on identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company leverages its deep expertise in clinical development and regulatory strategies to bring innovative therapies to patients with significant unmet medical needs. Protara's core product initiatives include TARA-002, an investigational cell therapy for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, a rare pediatric disease product candidate.
TARA Stock 12 Month Forecast
Average Price Target
$25.00
▲(361.25% Upside)
Technical Analysis
Protalix
―
TuHURA Biosciences
―
Skye Bioscience
―
Orchestra BioMed Holdings
―
Zura Bio
―
Ownership Overview
3.07% Insiders
4.99% Mutual Funds
23.43% Other Institutional Investors
62.58% Public Companies and Individual Investors
Options Prices
Currently, No data available
---